CYBN:CC News and Press, CYBIN INC. From 11/03/22

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at ...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce its participation in the following upcoming invest...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in...

– Cybin’s Director of Neuropharmacology, Amy Reichelt Ph.D. to present a talk titled “CYB004-Modifications to DMT to Enhance its Therapeutic Potential” – Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle ...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics ® ”, today announced the graduation of highly-skilled facilita...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever nov...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to res...

-- Cybin and The Chopra Foundation continue to work together to advance the research and education of psychedelic-based therapeutics as a new paradigm for the treatment of mental health -- Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or t...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cyb...